View by Year:
The pro-resolving lipid mediator maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth muscle and endothelial cells.
PloS one, 2014;[epublish]9(11):e113480.
D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Jun-2013;27(6):2220-32. Epub 2013 Mar 15.
Sex-based differences in the inflammatory profile of peripheral artery disease and the association with primary patency of lower extremity vein bypass grafts.
Journal of vascular surgery, Aug-2012;56(2):387-95; discussion 395. Epub 2012 May 25.
Chemical mediators of inflammation and resolution in post-operative abdominal aortic aneurysm patients.
RNA interference-mediated survivin gene knockdown induces growth arrest and reduced migration of vascular smooth muscle cells.
American journal of physiology. Heart and circulatory physiology, Nov-2011;301(5):H1841-9. Epub 2011 Aug 19.
Mineralocorticoid receptor expression in human venous smooth muscle cells: a potential role for aldosterone signaling in vein graft arterialization.
American journal of physiology. Heart and circulatory physiology, Jul-2011;301(1):H41-7. Epub 2011 May 2.
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.
The American journal of pathology, Oct-2010;177(4):2116-23. Epub 2010 Aug 13.
Challenges of distal bypass surgery in patients with diabetes: patient selection, techniques, and outcomes.
Journal of vascular surgery, Sep-2010;52(3 Suppl):96S-103S.
Multi-contrast high spatial resolution black blood inner volume three-dimensional fast spin echo MR imaging in peripheral vein bypass grafts.
The international journal of cardiovascular imaging, Aug-2010;26(6):683-91. Epub 2010 Mar 24.
Novel adipokines, high molecular weight adiponectin and resistin, are associated with outcomes following lower extremity revascularization with autogenous vein.
Journal of vascular surgery, May-2010;51(5):1152-9. Epub 2010 Mar 11.
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia.
Journal of vascular surgery, May-2010;51(5 Suppl):69S-75S.
Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia.
Journal of vascular surgery, Dec-2009;50(6):1462-73.e1-3. Epub 2009 Nov 7.
Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study.
Journal of vascular surgery, Dec-2009;50(6):1359-68.e1.
Technical factors in lower-extremity vein bypass surgery: how can we improve outcomes?
Seminars in vascular surgery, Dec-2009;22(4):227-33.
In vivo human lower extremity saphenous vein bypass grafts manifest flow mediated vasodilation.
Journal of vascular surgery, Nov-2009;50(5):1063-70. Epub 2009 Aug 12.